Skip to main navigation Skip to search Skip to main content

A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis

  • DADA – Dupilumab for Atopic Dermatitis of the Adolescence Study Group

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e384-e388
JournalJournal of the European Academy of Dermatology and Venereology
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this